Find a CARVYKTI ® Certified Treatment Center
Find a CARVYKTI® Certified Treatment Center with doctors and nurses specially trained in CAR-T-Cell therapy. See Safety & Prescribing info, including Boxed Warning.
CARVYKTI® (ciltacabtagene autoleucel) Certified Treatment Centers
Find a CARVYKTI® Certified Treatment Center, the only institutions authorized to prescribe & administer CARVYKTI®. See Safety & Prescribing info, including Boxed Warning.
Patient Website | CARVYKTI® (ciltacabtagene autoleucel)
CARVYKTI ® (ciltacabtagene autoleucel) is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at least one other treatment has not worked or has stopped working.
CARVYKTI® treatment is available only at CARVYKTI® Certified Treatment Centers. These are Certified Treatment Centers where doctors and nurses can prepare you for CAR-T therapy, administer CARVYKTI®, and mitigate potential side effects. The healthcare team at your Certified Treatment Center will partner with your primary oncologist to ...
CARVYKTI® is the First and Only BCMA-Targeted Treatment …
Apr 6, 2024 · CARVYKTI ® is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s own T-cells with a transgene encoding chimeric antigen receptor (CAR) that directs the CAR …
CARVYKTI (ciltacabtagene autoleucel) - International Myeloma …
May 7, 2024 · Carvykti is the first B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with myeloma as early as first relapse. The new approval makes this important chimeric antigen receptor (CAR) T-cell therapy available to patients earlier in their treatment journey.
Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted …
Dec 11, 2023 · CARVYKTI ® is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s own T-cells with a transgene encoding chimeric antigen receptor (CAR) that directs the CAR …
U.S. FDA Approves CARVYKTI™ (ciltacabtagene ...
CARVYKTI™ is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express the …
FDA Approves CARVYKTI® and ABECMA for Early Treatment of …
Apr 8, 2024 · CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) is now FDA-approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent and are refractory to lenalidomide and ABECMA® (idecabtagene vicleucel;ide ...
Treatment Process | CARVYKTI® (ciltacabtagene autoleucel) HCP
CARVYKTI® is administered in a single infusion that takes approximately 30 to 60 minutes at a CARVYKTI® Certified Treatment Center. Patients should remain within proximity of the CARVYKTI® Certified Treatment Center for at least 4 weeks following infusion.
- Some results have been removed